What was responding to said "data" not approval. If there is "approval" then there will be revenue. I don't believe we see approval until 2023 after pediatric Rett trial as long as it's very good. Avatar Rett trial I don't believe will get Anavex any "approval".
Yes, for sure Wall Street and other investors will not buy AVXL even after regulatory approvals that precede sales. After all, a regulatory approval is pretty meaningless -- it has no implications for revenue, right?
You make an excellent point. Once it is clear that the AVXL CNS cellular Homeostasis model has been substantially validated and verified (FDA-unrestricted) (multiple instances/indications) then, I claim, some exponential rule of value must be applied to sp. We can see where 30+ year old rules are not ready.
In solid state physics there are example of "thermal runaway"...(see 787 battery fires) where a material gets hotter b/c it is getting hotter Also can occur in certain semiconductors. When thermal runaway happens (no established precedent in W/s) how will AVXL be managed? I guess STOPS GALORE. Our day is coming soon, some will see it and be made wealthy while others will just observe. (ALL, IMO)
Yes, for sure Wall Street and other investors will not buy AVXL even after regulatory approvals that precede sales. After all, a regulatory approval is pretty meaningless -- it has no implications for revenue, right?
That is actually partly true. Distribution channels/partnerships need to be set up and packaging needs to be approved by the FDA. I saw a case where there mysteriously was a “typo” on the label submitted which delayed the “process” causing the stock to crater. Shorts had a field day. Mole? Many of them out there Im sure.
If we are being lead by good management than manufacturing and distribution will be settled ahead of time and “stock piling” the drug would be a good idea too to make sure there are no “shortages” or “delays”!